AnchorDx, Inc. is committed to building a world-class high-throughput sequencing clinical application and research and development platform, and becoming the world's leading provider of precision medicine overall solutions. Based on its core technological advantages, the company is geared to precision medicine, and has established cooperative relationships with upstream, midstream and downstream enterprises and institutions in the industry to form a complete industrial chain from academic resear...
Diagnostic Services and Products
- Clinical Diagnostic Laboratory Services
- Biomarker testing services
- Molecular/genetic laboratory diagnostic testing
- Diagnostic assay development/manufacturing
- Diagnostic Technologies/Capabilities
- (13.Sep.2021) AnchorDx Develops New Liquid Biopsy Diagnostic Model for Early Detection of Breast Cancer
- (21.Jul.2021) AnchorDx's Non-Invasive Bladder Cancer Early Detection Test, UriFind, Earns "Breakthrough Device Designation" From FDA
- (21.Jun.2021) 2021 ASCO - AnchorDx Unveils Robust Validation Result of Multi-Cancer Screening Technology AURORA
- (28.Apr.2021) AnchorDx Jointly Publishes Clinical Research Paper: "Accurate Diagnosis of Pulmonary Nodules Using a Non-Invasive DNA Methylation Test"
- (19.Apr.2021) AACR Annual Meeting 2021: AnchorDx Unveils High-Performance Blood Test for Gastric Cancer Screening
- (22.Feb.2021) AnchorDx Completes USD 40 Million Series C Financing to Advance Cancer Screening and Early Detection Programs
- (13.Oct.2020) AnchorDx, Inc. UriFind Bladder Cancer Non-Invasive Diagnostic Product Has Completed the EU CE Certification and Obtained the IVD Registration License Issued by the Dutch CIBG Authority